First-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2L advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial

Abstract

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, DEC 01-03, 2023